How Will the Market React to Panbela Therapeutics Inc (PBLA) Stock Getting a Bullish Rating

Overall market sentiment has been high on Panbela Therapeutics Inc (PBLA) stock lately. PBLA receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Panbela Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PBLA!

See Full PBLA Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With PBLA Stock Today?

Panbela Therapeutics Inc (PBLA) stock has risen 4.23% while the S&P 500 is down -0.25% as of 9:31 AM on Tuesday, Sep 5. PBLA is higher by $0.06 from the previous closing price of $1.42 on volume of 401,020 shares. Over the past year the S&P 500 has gained 15.26% while PBLA is down -99.79%. PBLA lost -$440.85 per share in the over the last 12 months. To screen for more stocks like Panbela Therapeutics Inc click here.

More About Panbela Therapeutics Inc

Panbela Therapeutics Inc is a clinical stage drug development company. It is engaged in the commercial development of a proprietary polyamine analogue for pancreatic cancer and for the second indication in chronic pancreatitis. The firm has developed a polyamine analogue compound referred as SBP-101 for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. Click Here to get the full Stock Report for Panbela Therapeutics Inc stock.